Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000591411 | SCV000703433 | benign | not specified | 2016-11-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000860742 | SCV001000884 | benign | Autosomal recessive polycystic kidney disease | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000860742 | SCV001325522 | uncertain significance | Autosomal recessive polycystic kidney disease | 2018-01-12 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
Genome- |
RCV001449937 | SCV001653391 | likely benign | Polycystic kidney disease 4 | 2021-05-18 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000591411 | SCV002571033 | likely benign | not specified | 2022-07-12 | criteria provided, single submitter | clinical testing | Variant summary: PKHD1 c.2168G>T (p.Arg723Leu) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0015 in 250710 control chromosomes (gnomAD), predominantly at a frequency of 0.01 within the South Asian subpopulation in the gnomAD database, including 4 homozygotes. The observed variant frequency within South Asian control individuals in the gnomAD database is approximately 1.41 fold of the estimated maximal expected allele frequency for a pathogenic variant in PKHD1 causing Polycystic Kidney And Hepatic Disease (0.0071), suggesting that the variant is a benign polymorphism found primarily in populations of South Asian origin. c.2168G>T has been reported in the literature in one heterozygous individual affected with Polycystic Kidney Disease, however this individual also carried a different pathogenic variant in the PKD1 gene (c.6040C>T, p.Gln2014Ter) that was determined to be the cause of the patient's phenotype (Eisenberger_2014). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five ClinVar submitters have assessed the variant since 2014: one classified the variant as VUS, one as likely benign, and three as benign. Based on the evidence outlined above, the variant was classified as likely benign. |
Ce |
RCV003431134 | SCV004163602 | benign | not provided | 2023-01-01 | criteria provided, single submitter | clinical testing | PKHD1: BP4, BS1, BS2 |
Natera, |
RCV000860742 | SCV001463504 | benign | Autosomal recessive polycystic kidney disease | 2019-12-17 | no assertion criteria provided | clinical testing |